|
WO2017178404A1
|
|
Combination therapies for the treatment of pancreatic cancer
|
|
WO2017174681A1
|
|
Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases
|
|
WO2017167763A1
|
|
Methods for diagnosis of haemorrhagic atherothrombotic plaques
|
|
WO2017162722A1
|
|
Free functional annexin levels in plasma as a biomarker of cardiovascular risk
|
|
WO2017162759A1
|
|
Methods and kits of assessing status, risk or prognosis of type 1 diabetes
|
|
WO2017158078A1
|
|
Endoscope and method for exploring a peritoneum
|
|
WO2017158043A1
|
|
Early and non invasive method for assessing a subject's risk of having pancreatic ductal adenocarcinoma and methods of treatement of such disease
|
|
WO2017149012A1
|
|
Peptides and uses thereof for reducing cd95-mediated cell motility
|
|
WO2017144546A1
|
|
Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
|
|
WO2017144471A1
|
|
Method for predicting whether a subject will achieve a lymphodepletion with an antibody specific for cd20
|
|
WO2017140845A1
|
|
Polypeptides for preparing drug conjugates capable of promoting apoptosis in a cell expressing an orexin receptor
|
|
WO2017140835A1
|
|
Methods and pharmaceutical compositions for the treatment of obesity
|
|
WO2017140743A1
|
|
Methods and pharmaceutical compositions for the treatment of multiple myeloma
|
|
WO2017134262A1
|
|
Use of aac-11 inhibitors for the treatment of viral infection
|
|
WO2017134252A1
|
|
Antisense oligonucleotides effective to reduce the expression of menin in cancer cells of a subject
|
|
WO2017134178A1
|
|
Imaging method for predicting the onset of multiple sclerosis
|
|
WO2017134043A1
|
|
Methods and pharmaceutical composition for neutralising the cytotoxic activity of extracellular histone proteins in subjects suffering from sepsis
|
|
WO2017129763A1
|
|
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
|
WO2017133984A1
|
|
Methods and pharmaceutical compositions for the prophylactic treatment of peritoneal carcinomatosis
|
|
WO2017129558A1
|
|
Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
|
